邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

miRNA在肝纤维化中的作用研究进展

黄璐,  吴有斌,  倪毅然,  刘梦媛,  吴江锋,  张艳琼

downloadPDF
文章导航 > 协和医学杂志  > 优先出版
黄璐, 吴有斌, 倪毅然, 刘梦媛, 吴江锋, 张艳琼. miRNA在肝纤维化中的作用研究进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2023-0125
引用本文: 黄璐, 吴有斌, 倪毅然, 刘梦媛, 吴江锋, 张艳琼. miRNA在肝纤维化中的作用研究进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2023-0125
shu
HUANG Lu, WU Youbin, NI Yiran, LIU Mengyuan, WU Jiangfeng, ZHANG Yanqiong. Research Progress on the Role of miRNA in Liver Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0125
Citation: HUANG Lu, WU Youbin, NI Yiran, LIU Mengyuan, WU Jiangfeng, ZHANG Yanqiong. Research Progress on the Role of miRNA in Liver Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0125
shu

miRNA在肝纤维化中的作用研究进展

doi: 10.12290/xhyxzz.2023-0125

  • 1 三峡大学 肿瘤微环境与免疫治疗湖北省重点实验室, 湖北宜昌 443002;

  • 2 三峡大学 基础医学院, 湖北宜昌 443002;

  • 3 三峡大学 器官纤维化与靶向治疗研究所, 湖北宜昌 443002;

  • 4 三峡大学人民医院 器官纤维化与靶向治疗研究所, 湖北宜昌 443099;

  • 5 三峡大学人民医院 病理科, 湖北宜昌 443099;

  • 6 宜昌人福药业有限责任公司, 湖北宜昌 443000

基金项目: 

国家自然科学基金（81670555）

详细信息
    通讯作者:

    张艳琼,E-mail:1512575383@qq.com

  • 中图分类号: Q527+.1;R34

Research Progress on the Role of miRNA in Liver Fibrosis

  • 1 Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University, Yichang, Hubei 443002, China;

  • 2 School of Basic Medicine, Three Gorges University, Yichang, Hubei 443002, China;

  • 3 Institute of Organ Fibrosis and Targeted Therapy, Three Gorges University, Yichang, Hubei 443002, China;

  • 4 Institute of Organ Fibrosis and Targeted Therapy, People's Hospital of Three Gorges University, Yichang, Hubei 443099, China;

  • 5 Department of Pathology, People's Hospital of Three Gorges University, Yichang, Hubei 443099, China;

  • 6 Yichang Renfu Pharmaceutical Co., Ltd., Yichang, Hubei 443000, China

Funds: 

National Natural Science Foundation （81670555）

    摘要
  • 摘要:

    微小RNA（micro RNAs， miRNA）参与多种疾病的病理及生理过程， 可稳定存在于组织、 细胞及血液中， 成为多种疾病诊断的潜在生物标志物。已有研究表明， 其在各种慢性肝病所致的肝纤维化中发挥重要作用，可通过调节肝纤维化相关基因的表达，干预肝纤维化发展进程。 本文就 miRNA 在肝纤维化中的作用研究进展作一综述， 以期为肝纤维化的诊断及分子靶向治疗提供借鉴。

    Abstract:

    Micro RNAs are involved in the pathophysiological processes of many diseases. Stably present in tissues, cells and blood, they can be used as potential markers of many diseases. They play an important role in the pathogenesis of liver fibrosis caused by various chronic liver diseases. It has been shown that miRNAs can participate in the process of liver fibrosis by targeting the down-regulation of liver fibrosis-related gene expression. In this review, we discuss the research progress on the role of miRNAs in liver fibrosis, with the hope of providing reference for diagnosis and molecularly targeted treatment.

    • HTML全文
    • 参考文献(56)
  • [1] Wang H, Wang Z, Wang Y, et al.miRNA-130b-5p promotes hepatic stellate cell activation and the development of liver fibrosis by suppressing SIRT4 expression[J]. J Cell Mol Med, 2021, 25:7381- 7394.
    [2] Szabo G, Bala S. MicroRNAs in liver disease[J]. Nat Rev Gastroenterol Hepatol, 2013, 10:542- 552.
    [3] Bhaskaran M, Mohan M. MicroRNAs:history, biogenesis, and their evolving role in animal development and disease[J]. Vet Pathol, 2014, 51:759-774.
    [4] Michlewski G, Caceres JF. Post-transcriptional control of miRNA biogenesis[J]. RNA, 2019, 25:1-16.
    [5] Li M, Yu B, Recent advances in the regulation of plant miRNA biogenesis[J]. RNA Biol, 2021, 18:2087-2096.
    [6] Suzuki HI, Young RA, Sharp PA. Super-Enhancer-Mediated RNA Processing Revealed by Integrative MicroRNA Network Analysis[J]. Cell, 2017, 168:1000-1014.
    [7] Nguyen TA, Park J, Dang TL, et al. Microprocessor depends on hemin to recognize the apical loop of primary microRNA[J]. Nucleic Acids Res, 2018, 46:5726-5736.
    [8] Alarcon CR, Lee H, Goodarzi H, et al. N6-methyladenosine marks primary microRNAs for processing[J]. Nature, 2015, 519:482-485.
    [9] Li H, Li X, Yu S, et al. miR-23b Ameliorates nonalcoholic steatohepatitis by targeting Acyl-CoA thioesterases 4[J]. Exp Cell Res, 2021, 407:112787.
    [10] El-Hefny M, Fouad S, Hussein T, et al. Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients[J]. J Med Virol, 2019, 91:93-101.
    [11] Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs[J]. Elife., 2015, 4:e05005.
    [12] Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis[J]. Hepatology, 2011, 53:209-218.
    [13] Yu X, Elfimova N, Muller M, et al. Autophagy-Related Activation of Hepatic Stellate Cells Reduces Cellular miR-29a by Promoting Its Vesicular Secretion[J]. Cell Mol Gastroenterol Hepatol, 2022, 13:1701-1716.
    [14] Matsumoto Y, Itami S, Kuroda M, et al. MiR-29a Assists in Preventing the Activation of Human Stellate Cells and Promotes Recovery From Liver Fibrosis in Mice[J]. Mol Ther, 2016, 24:1848-1859.
    [15] Girard M, Jacquemin E, Munnich A, et al. miR-122, a paradigm for the role of microRNAs in the liver[J]. J Hepatol, 2008, 48:648-656.
    [16] Sendi H, Mead I, Wan M, et al. miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling[J]. PLOS ONE, 2018, 13:e200847.
    [17] Satishchandran A, Ambade A, Rao S, et al. MicroRNA 122, Regulated by GRLH2, Protects Livers of Mice and Patients From Ethanol-Induced Liver Disease[J]. Gastroenterology, 2018, 154:238-252.
    [18] Zeng C, Wang YL, Xie C, et al. Identification of a novel TGF-beta-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis[J]. Oncotarget, 2015, 6:12224-12233.
    [19] Li J, Ghazwani M, Zhang Y, et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression[J]. J Hepatol, 2013, 58:522-528.
    [20] Wu Z, Wang J, Feng J, et al. MicroRNA-122-5p prevents proliferation and promotes apoptosis of hepatic stellate cells by suppressing the cellular-Abelsongene/histone deacetylases 2 pathway[J]. Hum Exp Toxicol, 2022, 41:774864384.
    [21] Omran AA, Osman KS, Kamel H M, et al. MicroRNA-122 as a Novel Non-Invasive Marker of Liver Fibrosis in Hepatitis C Virus Patients[J]. Clin Lab, 2016, 62:1329-1337.
    [22] Lou G, Yang Y, Liu F, et al. MiR-122 modification enhances the therapeutic efficacy of adipose tissue-derived mesenchymal stem cells against liver fibrosis[J]. J Cell Mol Med, 2017, 21:2963-2973.
    [23] Kim K, Lee JI, Kim O, et al. Ameliorating liver fibrosis in an animal model using the secretome released from miR-122-transfected adipose-derived stem cells[J]. World Journal of Stem Cells, 2019, 11:990-1004.
    [24] Yan G, Li B, Xin X, et al. MicroRNA-34a Promotes Hepatic Stellate Cell Activation via Targeting ACSL1[J]. Med Sci Monit, 2015, 21:3008-3015.
    [25] Li X, Chen Y, Wu S, et al. microRNA-34a and microRNA-34c promote the activation of human hepatic stellate cells by targeting peroxisome proliferator-activated receptor gamma[J]. Mol Med Rep, 2015, 11:1017-1024.
    [26] Song L, Chen TY, Zhao XJ, et al. Pterostilbene prevents hepatocyte epithelial-mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGFbeta1/Smads signalling[J]. Br J Pharmacol, 2019, 176:1619-1634.
    [27] Tian XF,Ji FJ,Zang HL,et al. Activation of the miR-34a/SIRT1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis via Inducing Apoptosis in Hepatocytes but Not in HSCs[J]. PLoS One, 2016, 11:e158657.
    [28] Liu Q, Zhang Y, Yang S, et al. PU.1-deficient mice are resistant to thioacetamide-induced hepatic fibrosis:PU.1 finely regulates Sirt1 expression via transcriptional promotion of miR-34a and miR-29c in hepatic stellate cells[J]. Biosci Rep, 2017, 37:BSR20170926.
    [29] Li X, Zhang W, Xu K, et al. miR-34a promotes liver fibrosis in patients with chronic hepatitis via mediating Sirt1/p53 signaling pathway[J]. Pathol Res Pract, 2020, 216:152876.
    [30] Messner CJ, Schmidt S, Ozkul D, et al. Identification of miR-199a-5p, miR-214-3p and miR- 99b-5p as Fibrosis-Specific Extracellular Biomarkers and Promoters of HSC Activation[J]. Int J Mol Sci, 2021, 22:9799.
    [31] Murakami Y, Toyoda H, Tanaka M, et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families[J]. PLoS One, 2011, 6:e16081.
    [32] Lino CC, Henaoui IS, Courcot E, et al. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1[J]. PLoS Genet, 2013, 9:e1003291.
    [33] Yang X, Ma L, Wei R, et al. Twist1-induced miR-199a-3p promotes liver fibrosis by suppressing caveolin-2 and activating TGF-beta pathway[J]. Signal Transduct Target Ther, 2020, 5:75.
    [34] Pineau P, Volinia S, Mcjunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis[J]. Proc Natl Acad Sci USA, 2010, 107:264-269.
    [35] Ogawa T, Enomoto M, Fujii H, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis[J]. Gut, 2012, 61:1600-1609.
    [36] Galardi S, Mercatelli N, Farace M G, et al. NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells[J]. Nucleic Acids Res, 2011, 39:3892-3902.
    [37] Sehgal M, Zeremski M, Talal AH, et al. IFN-alpha-Induced Downregulation of miR-221 in Dendritic Cells:Implications for HCV Pathogenesis and Treatment[J]. J Interferon Cytokine Res, 2015, 35:698-709.
    [38] Mafanda EK, Kandhi R, Bobbala D, et al. Essential role of suppressor of cytokine signaling 1(SOCS1) in hepatocytes and macrophages in the regulation of liver fibrosis[J]. Cytokine, 2019, 124:154501.
    [39] Jiang X, Jiang L, Shan A, et al. Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice[J]. EBioMedicine, 2018, 37:307-321.
    [40] Markovic J, Sharma AD, Balakrishnan A. MicroRNA-221:A Fine Tuner and Potential Biomarker of Chronic Liver Injury[J]. Cells, 2020, 9:1767.
    [41] Blaya D, Aguilar-Bravo B, Hao F, et al. Expression of microRNA-155 in inflammatory cells modulates liver injury[J]. Hepatology, 2018, 68:691-706.
    [42] Bala S, Csak T, Saha B, et al. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis[J]. J Hepatol, 2016, 64:1378-1387.
    [43] Bala S, Ganz M, Babuta M, et al. Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH[J]. Laboratory Investigation, 2021, 101:1540-1549.
    [44] Dai W, Zhao J, Tang N, et al. MicroRNA-155 attenuates activation of hepatic stellate cell by simultaneously preventing EMT process and ERK1 signalling pathway[J]. Liver Int, 2015, 35:1234- 1243.
    [45] Niu LJ, Zhang YM, Huang T, et al. Exosomal microRNA-155 as a biomarker for hepatic fibrosis diagnosis and progression[J]. Ann Transl Med, 2021, 9:137.
    [46] Wang Y, Luo J, Zhang H, et al. microRNAs in the Same Clusters Evolve to Coordinately Regulate Functionally Related Genes[J]. Mol Biol Evol, 2016, 33:2232-2247.
    [47] Wan LY, Peng H, Ni YR, et al. The miR-23b/27b/24-1 Cluster Inhibits Hepatic Fibrosis by Inactivating Hepatic Stellate Cells[J]. Cell Mol Gastroenterol Hepatol, 2022, 13:1393-1412.
    [48] Hong SW, Jung KH, Zheng HM, et al. The protective effect of resveratrol on dimethylnitrosamineinduced liver fibrosis in rats[J]. Arch Pharm Res, 2010, 33:601-609.
    [49] Pan Y, Wang J, He L, et al. MicroRNA-34a Promotes EMT and Liver Fibrosis in Primary Biliary Cholangitis by Regulating TGF-beta1/smad Pathway[J]. J Immunol Res, 2021, 2021:6890423.
    [50] Harrison SA, Ratziu V, Boursier J, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis:a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5:970-985.
    [51] Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours[J]. Br J Cancer, 2020, 122:1630-1637.
    [52] 陆伦根,尤红,谢渭芬,等. 肝纤维化诊断及治疗共识(2019年)[J]. 实用肝脏病杂志, 2019, 22:793-803.
    [53] Hassan S, Syed S, Kehar SI. Review of diagnostic techniques of hepatic fibrosis[J]. J Pak Med Assoc, 2014, 64:941-945.
    [54] Dana J, Venkatasamy A, Saviano A, et al. Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease[J]. Hepatol Int, 2022, 16:509-522.
    [55] Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility[J]. Nat Biotechnol, 2017, 35:238-248.
    [56] Yamamoto T, Mukai Y, Wada F, et al. Highly Potent GalNAc-Conjugated Tiny LNA AntimiRNA-122 Antisense Oligonucleotides[J]. Pharmaceutics, 2021, 13:817.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  21
  • HTML全文浏览量:  5
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-03-13
  • 网络出版日期:  2023-05-08

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！